Actionable news
All posts from Actionable news
Actionable news in CELG: Celgene Corporation,

bluebird bio to Present New Data from Clinical Studies of LentiGlobin

- 11 total abstracts accepted, including updated data from Northstar-2 (HGB-207) Phase 3 study of LentiGlobin in patients with TDT and non-β00 genotypes, HGB-205 study of LentiGlobin in patients with SCD and TDT, and CRB-401 study of bb2121 anti-BCMA CAR T in patients with relapsed/refractory multiple myeloma along with preclinical abstract data -

- Results from two subjects with SCD in LentiGlobin study HGB-206 treated under amended study protocol provide early indication of improved drug product vector copy numbers (DP VCN), in vivo VCN and HbAT87Q hemoglobin production -

- Clinical data indicate that use of single-agent plerixafor for stem cell mobilization is well tolerated by patients with SCD and may enable increased cell doses and a more favorable phenotype with fewer lineage committed lymphoid progenitors compared to bone marrow harvest; plerixafor mobilization clinical study cohort has been implemented in HGB-206 study -

- Data on patients with up to three-year follow up data from patients in the Northstar (HGB-204) study of LentiGlobin drug product in TDT demonstrate durability of treatment and potential for improved hemoglobin production over time -

- Company to hold conference call and webcast today, November 1, at 8:30 a.m. ET -